electroCore secures two new US patents for nerve therapy

ROCKAWAY, N.J. - electroCore, Inc. (NASDAQ:ECOR), a bioelectronic medicine company with a market capitalization of approximately $105 million, has been granted two new patents by the United States Patent and Trademark Office. The patents cover advancements in nerve stimulation therapy and remote patient monitoring technology. According to InvestingPro data, the company has shown remarkable momentum with a 175% price return over the past six months.

The first patent, US Patent No. 12,208,263, issued on January 28, 2025, details methods for stimulating the vagus nerve. This involves placing an electrode with a conductive gel on the user’s neck to deliver electrical impulses to the nerve. The electrode’s position can be adjusted based on the pressure sensation against the neck.

The second patent, US Patent No. 12,213,795, granted on February 4, 2025, describes systems for modulating a nerve while storing data on the parameters of the electrical impulse applied. It also includes collecting user status data, like headache severity, and comparing it with the impulse parameters.

electroCore’s focus is on the commercialization of medical devices for managing and treating specific medical conditions, as well as consumer products that use non-invasive vagus nerve stimulation (nVNS) to promote general well-being.

The announcement of these patents represents a step forward for electroCore in terms of expanding its intellectual property portfolio. However, the company’s press release also contains forward-looking statements, and as such, the actual outcomes could vary due to various factors, including market conditions and competition.

Investors and interested parties are advised that the information shared here is based on a press release statement from electroCore. Further details on the company’s strategies and product development will be subject to future developments and regulatory outcomes.

In other recent news, electroCore Inc. has been making significant strides in its financial performance and strategic expansion. The company recently announced a definitive merger agreement to acquire NeuroMetrix (NASDAQ:NURO), Inc., a significant move expected to expand electroCore’s product offerings and enhance its position in the medical device market for pain management. This development prompted H.C. Wainwright to increase its price target for electroCore from $22.00 to $25.00, while maintaining a Buy rating on the stock.

The merger is expected to incorporate revenues from NeuroMetrix’s Quell product line beginning in the second quarter of 2025, contributing to electroCore’s revenue streams. This follows the company’s record Q3 revenue of $6.6 million, up 45% year-over-year, and a narrowed net loss to $2.5 million, or $0.31 per share.

In other financial forecasts, H.C. Wainwright has projected total revenues for electroCore to reach $25.4 million for the full year of 2024, with a net loss of $1.54 per diluted share. These recent developments highlight the company’s strategic decisions and financial performance, offering investors a glimpse into electroCore’s future operations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.